MX2010005950A - 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. - Google Patents
2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors.Info
- Publication number
- MX2010005950A MX2010005950A MX2010005950A MX2010005950A MX2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A MX 2010005950 A MX2010005950 A MX 2010005950A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- methods
- fluoropyrazolo
- pyrimidines
- protein kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pyrazolo[1,5-a]pyrimidine-based inhibitors of various kinase, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions that contain such inhibitors are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 or CHK-1 inhibitor compounds, methods of inhibiting CDK-2 or CHK-1, and methods for treating disease or disease symptoms.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99073607P | 2007-11-28 | 2007-11-28 | |
PCT/US2008/084643 WO2009070567A1 (en) | 2007-11-28 | 2008-11-25 | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010005950A true MX2010005950A (en) | 2010-06-17 |
Family
ID=40343608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005950A MX2010005950A (en) | 2007-11-28 | 2008-11-25 | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2225247A1 (en) |
JP (1) | JP2011504931A (en) |
CN (1) | CN101970440A (en) |
CA (1) | CA2706946A1 (en) |
MX (1) | MX2010005950A (en) |
WO (1) | WO2009070567A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3372605T (en) | 2008-10-22 | 2022-02-10 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
KR102132405B1 (en) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Macrocyclic compounds as trk kinase inhibitors |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
ES2946360T3 (en) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as ATR kinase inhibitors for the treatment of cancer diseases |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
RU2687276C2 (en) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Compounds suitable for use as atr kinase inhibitors |
WO2015097121A1 (en) | 2013-12-23 | 2015-07-02 | Norgine B.V. | Compounds useful as ccr9 modulators |
LT3152212T (en) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
BR112017009207A2 (en) | 2014-11-03 | 2019-10-01 | Bayer Pharma AG | piperidinylpyrazolopyrimidinones and their use |
EP3215511B1 (en) | 2014-11-06 | 2024-04-17 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
ES2958391T3 (en) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
AU2015342883B2 (en) | 2014-11-06 | 2020-07-02 | Bial - R&D Investments, S.A. | Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders |
RS64122B1 (en) | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
BR112017013031A2 (en) * | 2014-12-19 | 2018-01-02 | Janssen Pharmaceutica Nv | heterocyclyl-linked imidazopyridazine derivatives as pi3kbeta inhibitors |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
BR112018008357A2 (en) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | dot mutations in trk inhibitor resistant cancer and related methods |
AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MX2018012208A (en) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders. |
EP3440080A4 (en) | 2016-04-06 | 2020-01-22 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
HRP20230704T1 (en) | 2016-05-18 | 2023-10-27 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
MX2019003136A (en) | 2016-09-19 | 2019-07-18 | Bayer Cropscience Ag | Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides. |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
WO2021176045A1 (en) * | 2020-03-06 | 2021-09-10 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
US20230183211A1 (en) * | 2020-06-01 | 2023-06-15 | Unimatec Co., Ltd. | Fluorine-containing fused ring pyrimidine compound and method for producing same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550470B2 (en) * | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
CA2516824A1 (en) * | 2003-02-28 | 2004-09-10 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivatives |
JP2008531656A (en) * | 2005-03-02 | 2008-08-14 | ビーエーエスエフ ソシエタス・ヨーロピア | 2-substituted 7-aminoazolopyrimidines, methods for their preparation and their use in controlling pathogenic fungi, and agents containing the compounds |
-
2008
- 2008-11-25 MX MX2010005950A patent/MX2010005950A/en not_active Application Discontinuation
- 2008-11-25 CA CA2706946A patent/CA2706946A1/en not_active Abandoned
- 2008-11-25 WO PCT/US2008/084643 patent/WO2009070567A1/en active Application Filing
- 2008-11-25 CN CN2008801257650A patent/CN101970440A/en active Pending
- 2008-11-25 EP EP08854702A patent/EP2225247A1/en not_active Withdrawn
- 2008-11-25 JP JP2010536116A patent/JP2011504931A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2706946A1 (en) | 2009-06-04 |
WO2009070567A1 (en) | 2009-06-04 |
JP2011504931A (en) | 2011-02-17 |
EP2225247A1 (en) | 2010-09-08 |
CN101970440A (en) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010005950A (en) | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. | |
ZA200707342B (en) | Pyrrolopyrimidines useful as inhibitors of protein kinase | |
TW200801008A (en) | Protein kinase inhibitors | |
ZA200702645B (en) | Diaminotriazole compounds useful as protein kinase inhibitors | |
MXPA06010904A (en) | Tricyclic pyrazole kinase inhibitors. | |
TW200736249A (en) | Aminopyrimidines useful as kinase inhibitors | |
MX2009003734A (en) | Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor. | |
NO20072567L (en) | Triazoles useful as protein kinase inhibitors | |
WO2006050109A3 (en) | Novel kinase inhibitors | |
TW200745128A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
MX2009012066A (en) | Substituted imidazopyridazines as pi3k lipid kinase inhibitors. | |
GEP20125368B (en) | Kinase inhibitors | |
TW200745127A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
MX2008005398A (en) | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer. | |
TW200745123A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
MX2009006690A (en) | Aminopyrimidines useful as inhibitors of protein kinases. | |
TW200514776A (en) | Aminotriazole compounds useful as inhibitors of protein kinases | |
WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
MX2009005144A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors. | |
IL200793A0 (en) | Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases | |
ECSP088906A (en) | PIRAZOLO 1,5-a PYRIMIDINS | |
MX2009004623A (en) | Imidazopyridazines as pi3k lipid kinase inhibitors. | |
MX2009003733A (en) | Pyrazolopyrimidines as cyclin dependent kinase inhibitors. | |
MX2009004771A (en) | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase. | |
WO2005076854A3 (en) | Pyrimidinone compounds useful as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |